Complications of critical illness: Rationale for prophylactic strategies

Clinical Pulmonary Medicine

Volumn 12, Issue 4, 2005, Pages 258-268

  Patel, Gourang P ^a,b   Liberman, Joshua ^a   Gurka, David ^a   Elpern, Ellen ^a   Balk, Robert A ^a  

^a RUSH MEDICAL COLLEGE   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Catheter related bloodstream infections; Complications; Critical illness; Gastrointestinal bleeding; Thromboembolism; Ventilator associated pneumonia

Indexed keywords

DALTEPARIN; ENOXAPARIN; HEPARIN; HISTAMINE H2 RECEPTOR ANTAGONIST; LOW MOLECULAR WEIGHT HEPARIN; PROTON PUMP INHIBITOR; SUCRALFATE;

ANTIBIOTIC THERAPY; ARTIFICIAL VENTILATION; CATHETER INFECTION; CLINICAL PROTOCOL; CLINICAL TRIAL; CRITICAL ILLNESS; DRUG EFFICACY; HEALTH CARE COST; HIGH RISK PATIENT; HOSPITAL HYGIENE; HOSPITAL PERSONNEL; HUMAN; INTENSIVE CARE; MEDICAL EDUCATION; MORBIDITY; MORTALITY; PRACTICE GUIDELINE; PROPHYLAXIS; REVIEW; STRESS RELATED MUCOSAL DISEASE; STRESS ULCER; VENOUS THROMBOEMBOLISM; VENTILATOR ASSOCIATED PNEUMONIA;

EID: 23244466254     PISSN: 10680640     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cpm.0000171502.70787.f2     Document Type: Review

References (56)

1. Anderson FA, Wheeler HD, Goldberg RJ, et al. The Worcester DVT Study. Arch Intern Med. 1991;151:933-938.
2. Heit J, Silverstein M, Mohr D, et al. The epidemiology of venous thromboembolism in the community. Thromb Haemost. 2001;85:452-463.
3. Greets WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism. Chest. 2004;126:338s-400s
4. nd ed. McGraw Hill; 1998:1049-1052.
5. Zeltsman D, Rowland M, Shanavas Z, et al. Is the incidence of hemorrhagic stress ulceration in surgical critically ill patients affected by modern antacid prophylaxis? Am Surg. 1996;62:1010-1013.
6. Zandstra DF, Stoutenbeek CP. The virtual absence of stress-ulceration related bleeding in ICU patients receiving prolonged mechanical ventilation without any prophylaxis: a prospective cohort study. Intensive Care Med. 1994;20:335-340.
7. Greets W, Selby R. Prevention of venous thromboembolism in the ICU. Chest. 2003;124:357s-363s
8. Lechler E, Schramm W, Flosbach CW, et al. Venous thromboembolism risk in non-surgical patients: PRIME Study Group. Haemostasis. 1996; 26:49-56.
9. Bergmann J, Neuhart E. Multi-center, randomized, double-blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in-patients bedridden for an acute medical illness. Thromb Haemost. 1996;76:529-534.
10. Samama M, Cohen A, Darmon J, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients: MEDENOX Trial. N Engl J Med. 1999;34:793-800.
11. Kleber F, Witt C, Vogel G, et al. Randomized comparison of enoxaparin with unfractionated heparin for prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease: PRINCE Trial. Am Heart J. 2003,145:14-21.
12. Clarke-Pearson DL, Coleman RE, Synam IS, et al. Venous thromboembolism prophylaxis in gynecologic oncology: a prospective, controlled trial of low-dose heparin. Am J Obstet Gynecol. 1983;145:606-613.
13. 11a. Enders J, Burke J, Dobesh P. The prevention of venous thromboembolism in acute medical illness. Pharmacotherapy. 2002;22:1564-1578.
14. Kollef MH. Epidemiology and risk factors for nosocomial pneumonia: emphasis on prevention. Clin Chest Med. 1999;20:653-670.
15. 12a. Bergmann JF, Neuhart E. A multicenter randomized double-blind study of enoxaparin compared with unfractionated herapin in the prevention of venous thromboembolic disease in elderly in-patients bedridden for an acute medical illness. The Enoxaparin in Medicine Study Group. Thromb Haemost. 1996;76:529-534.
16. Meduri GU. Diagnosis and differential diagnosis of ventilator-associated pneumonia. Clin Chest Med. 1995;16:61-93.
17. A consensus statement. Am J Respir Crit Care Med. 1995;153:1711-1725.
18. Kollef MH. The prevention of ventilator-associated pneumonia. N Engl J Med. 1999;340:627-634.
19. Campbell. Am J Resp Crit Care Med. 1995.
20. Girous E, Schortgen F, Delclaux C, et al. Association of noninvasive ventilation with nosocomial infections and survival in critically ill patients. JAMA. 2000;284:2361-2367.
21. Rello J, Ollendorf D, Oster G, et al. Epidemiology and outcomes of ventilator-associated pneumonia in a large US database. Chest. 2002; 122:2115-2121.
22. Rello J, Paiva J, Baraibar J, et al. International conference for develop-ment of consensus on the diagnosis and treatment of ventilator- associated pneumonia. Chest. 2001;120:955-970.
23. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science. 1999;284:1318-1322.
24. Zack J, Garrison T, Trovillion E, et al. Effect of an educational program aimed at reducing the occurrence of ventilator-associated pneumonia. Crit Care Med. 2002;30:2407-2412.
25. Babcock H, Zack J, Garrison T, et al. An educational intervention to reduce ventilator-associated pneumonia in an integrated health-system. Chest. 2004;125:2224-2231.
26. Messori A, Trippoli S, Vaiani M, et al. Bleeding and pneumonia in intensive care patients given ranitidine and sucralfate for the prevention of stress ulcer: meta-analysis of randomized controlled trials. BMJ. 2000;321:1-7.
27. Mermel LA, Farr BM, Sherertz RJ, et al. Guidelines for the management of intravascular catheter-related infections. Clin Infect Dis. 2001;32: 1249-1272.
28. Saint S, Veenstra DL, Sullivan SD, et al. The potential clinical and economic benefits of silver alloy urinary catheters in preventing urinary tract infection. Arch Intern Med. 2000;160:2679-2675.
29. Peura DA, Johnson LF. Cimetidine for prevention and treatment of gastroduodenal mucosal lesions in patients in an intensive care unit. Ann Intern Med. 1985;103:173-177.
30. Chastre J, Wolff M, Fagon J, et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults. JAMA. 2003;290:2588-2598.
31. Micek S, Ward S, Fraser V, et al. A randomized controlled-trial of an antibiotic discontinuation policy for clinically suspected ventilator-associated pneumonia. Chest. 2004;125:1791-1799.
32. Kollef M. Prevention of hospital-associated pneumonia and ventilator-associated. Pneumonia Crit Care Med. 2004;32:1396-1405.
33. Trautuer B, Darouiche R. Catheter-associated infections. Arch Intern Med. 2004;164:842-850.
34. Mermel LA. Prevention of intravascular catheter-related infections. Ann Intern Med. 2000;132:391-402.
35. SafdarN, Maki D. The pathogenesis of catheter-associated bloodstream infections with non-cuffed short-term central venous catheters. Intensive Care Med. 2004;30:62-67.
36. MMWR Recomm Rep. 2002;51:1-29.
37. CDC: National Nosocomial Infections Surveillance (NNIS) system report, data summary from October 1986-April 1998, issued June 1998. Am J Infect Control. 1998;26:522-533.
38. Cicalini S, Palmiei F, Petrosillo N. Clinical review: new technologies for prevention of intravascular catheter-related infections. Crit Care. 2003; 7:Online.
39. Crnich C, Maki D. Are antimicrobial-impregnated catheters effective? don't throw out the baby with the bathwater. Clin Infect Dis. 2004;38: 1287-1292.
40. Chaiyakunapruk N, Veenstra DL, Lipsky BA, et al. Ann Intern Med. 2002;136:792-801.
41. Richet H, Hubert B, Nitemberg G, et al. Prospective multicenter study of vascular-catheter-related complications and risk factors for positive central-catheter cultures in intensive care unit patients. J Clin Microbiol. 1990;28:2520-2525.
42. Maki DG, Ringer M. Evaluation of dressing regimens for prevention of infection with peripheral intravenous catheters: gauze, a transparent Polyurethane dressing, and an iodophor-transparent dressing. JAMA. 1987;258:2396-2403.
43. Hoffmann KK, Weber DJ, Samsa GP, et al. Transparent polyurethane film as an intravenous catheter dressing: a meta-analysis of the infection risks. JAMA. 1992;267:2072-2076.
44. Cobb DK, High KP, Sawyer RG, et al. A controlled trial of scheduled replacement of central venous and pulmonary-artery catheters. N Engl J Med. 1992;327:1062-1068.
45. Robinson D, Suhocki P, Schwab SJ. Treatment of infected tunneled venous access hemodialysis catheters with guidewire exchange. Kidney Int. 1998;53:1792-1794.
46. Berenholtz SM, Pronovost PJ, Lipsett PA, et al. Eliminating catheter-related bloodstream infections in the intensive care unit. Crit Care Med. 2004;32:2014-2020.
47. Reilly J, Fennerty MB. Stress ulcer prophylaxis: the prevention of GI bleeding and the development of nosocomial infections in critically ill patients. J Pharm Pract. 1998;11:418-432.
48. Allen M, Kopp BJ, Erstad BL. Stress ulcer prophylaxis in the postoperative period. Am J Health Syst Pharm. 2004;61:588-596.
49. 45a. Halm U, Halm F, Thein D, et al. Helicobacter pylori infection: a risk factor for upper gastrointestinal bleeding after cardiac surgery? Crit Care Med. 2000;28:110-113.
50. 45b. Schilling D, Haisch G, Sloot N, et al. Low seroprevalence of Helicobacter pylori infection in patients with stress ulcer bleeding. Intensive Care Med. 2000;26:1832-1836.
51. Cook DJ, Fuller HD, Guyatt GH, et al. Risk factors for gastrointestinal bleeding in critically ill patients. N Engl J Med. 1994 330:377-381.
52. Devlin JW, Ben-Menachem T, Ulep SK, et al. Stress ulcer prophylaxis in medical ICU patients: annual utilization in relation to the incidence of endoscopically proven stress ulceration. Ann Pharmacother. 1998;32: 869-874.
53. Cook DJ, Reeve BK, Guyatt GH, et al. Stress ulcer prophylaxis in critically ill patients: resolving discordant meta-analyses. JAMA. 1996; 275:308-314.
54. Yasue N, Guth PH. Role of exogenous acid and retransfusion in hemorrhagic shock-induced gastric lesions in the rat. Gastroenterology. 1988;94:1135-1143.
55. Sloan JM, Correa P, Lindeman. J. The stomach: part 1. In: Whitehead R, ed. Gastrointestinal and Esophageal Pathology. New York: Churchill Livingstone; 1995:461-485.
56. Cook D, Heyland D, Griffith L, et al. Risk factors for clinically important upper gastrointestinal bleeding in patients requiring mechanical ventilation. Crit Care Med. 1999;27:2812-2817.